唐波,李伟,叶丽卡,王若伦,冯霞
TANG Bo,LI Wei,YE Lika,WANG Ruolun,FENG Xia

• 1:广州医科大学附属第二医院药学部
• 2:广州医科大学附属省武警医院消化内科

摘要(Abstract)：

目的观察阿德福韦酯、注射用重组人干扰素α2b治疗慢性乙型肝炎患者血清中miRNA的变化及临床意义。方法选取2012-05~2013-05省武警医院消化内科门诊的100例慢性乙型肝炎患者为研究对象,根据治疗用药不同,分为阿德福韦酯组和干扰素组各50例,分别口服阿德福韦酯胶囊5 mg/d和皮下注射干扰素针100万单位/周,应用芯片杂交技术分析患者在治疗期间血清中miR-122、miR-19b的变化。结果 miR-122、miR-19b在阿德福韦酯组治疗后的表达量分别为(75.26±13.43)(88.64±15.36)fmol/L,在干扰素组治疗后的表达量分别为(65.18±22.08)(69.32±25.17)fmol/L,各组治疗后各指标均高于治疗前,差异均有统计学意义(P<0.05),但2组间治疗前后差异无统计学意义(P>0.05)。结论阿德福韦酯与注射用重组人干扰素α2 b均可上调慢性乙型肝炎患者血清miR-122、miR-19b的表达,可能为其发挥作用的机制之一。
OBJECTIVE To study the change and clinical significance of expression of miRNA in the serum of chronic hepatitis B patients treated with adefovir dipivoxil( ADV) and interferon( IFN). METHODS A total of 100 cases of patients with chronic hepatitis B were selected as the research objects,and were divided into the ADV(5 mg / d) treatment group and the IFN( one million units per week) treatment group with 50 cases in each according to the different drug treatment. The expressions of miR-122 and miR-19 b in the serum of all the patients during the treatment were determined by microarray technology. RESULTS After the treatment,the contents of expression of miR-122,miR-19 b in the ADV treatment group were( 75. 26 ± 13. 43) and( 88. 64 ± 15. 36) fmol / L,which were(65. 18 ± 22. 08) and(69. 32 ± 25. 17) fmol / L in the IFN treatment group,all the indexes were higher after the treatment than before the treatment( P < 0. 05),there was no significant difference between 2 groups( P > 0. 05). CONCLUSION The increased contents of miR-122 and miR-19 b in the serum of the 2 groups were probably patent mechanism.

关键词(KeyWords)： 慢性乙型肝炎;miRNA;miR-122;miR-19b
chronic hepatitis B;miRNA;miR-122;miR-19b

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 唐波,李伟,叶丽卡,王若伦,冯霞
TANG Bo,LI Wei,YE Lika,WANG Ruolun,FENG Xia

参考文献(References)：

• [1]Lovis P,Gattesco S,Regazzi R.Regulation of the expression of components of the exocytotic machinery of insulin-secreting cells by micro RNAs[J].Biol Chem,2008,289(3):305-312.
• [2]Fassina A,Marino F,Siri M,et al.The miR-17-92 micro RNA cluster:a novel diagnostic tool in large B-cell malignancies[J].Lab Invest,2012,92(11):1574-1582.
• [3]Baraniskin A,Kuhnhenn J,Schlegel U,et al.Micro RNAs in cerebrospinal as biomarker for disease course monitoring in primary central nervous system lymphoma[J].J Neurooncol,2012,109(2):239-244.
• [4]Bukong TN,Lo T,Szabo G,et al.Novel developmental biology-based protocol of embryonic stem cell differentiation to morphologically sound and functional yet immature hepatocytes[J].Liver Int,2012,32(50):732-741.
• [5]Esau C,Davis S,Murray SF,et al.miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting[J].Cell Metab,2006,3(2):87-98.
• [6]Tzur G,Levy A,Meiri E,et al.Micro RNA expression patterns and function in endodermal differentiation of human embryonic stem cells[J].PLo S One,2008,3(11):e3726.
• [7]Kurokawa K,Tanahashi T,Lima T,et al.Role of miR-19b and its target m RNAs in 5-fluorouracil resistance in colon cancer cells[J].J Gastroenterol,2012,47(8):883-895.
• [8]Lakner AM,Steuerwald NM,Walling TL,et al.Inhibitory effects of micro RNA 19b in hepatic stellate cell-mediated fibrogenesis[J].Hepatology,2012,56(1):300-310.